2023 World Conference on Lung Cancer (Posters)-P2.06. First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN

P2.06. First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN - PDF(Slides)

Back to course

Pdf Summary

The document provides updated data from the CAP-BRAIN trial, which evaluated the efficacy and safety of first-line camrelizumab plus chemotherapy for patients with advanced non-squamous non-small cell lung cancer (NSCLC) and brain metastases (BMs). Approximately 25%-39% of patients with metastatic NSCLC have BMs at the initial diagnosis, and they usually have limited treatment options and poor outcomes.<br /><br />The updated results showed that the intracranial objective response rate (iORR) was 57.5% in the efficacy analysis set (EAS) and 51.1% in the full analysis set (FAS). The median intracranial progression-free survival (iPFS) was 8.4 months, with iPFS rates of 66.8% at 6 months and 47.1% at 12 months. The median overall progression-free survival (PFS) was 7.2 months, and the estimated 12-month overall survival (OS) rate was 65.9%.<br /><br />The treatment-related adverse events were manageable, with 35.6% of patients experiencing grade 3 or above events. No new safety signals were observed during the extended follow-up.<br /><br />The study also assessed the patients' cognitive ability and quality of life using the Montreal Cognitive Assessment (MoCA) and Functional Assessment of Cancer Therapy-Lung (FACT-L) scores, which showed positive trends.<br /><br />Patients who experienced disease progression received subsequent antitumor therapy, with the most common strategy being antiangiogenic agents plus chemotherapy. Some patients also received brain radiation therapy after progression.<br /><br />Overall, the updated data from the CAP-BRAIN trial demonstrate that camrelizumab plus chemotherapy continues to provide promising clinical outcomes for patients with advanced non-squamous NSCLC and BMs.

Asset Subtitle

xue hou

Meta Tag

Speaker xue hou

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

CAP-BRAIN trial

camrelizumab

chemotherapy

non-squamous non-small cell lung cancer

brain metastases

intracranial objective response rate

intracranial progression-free survival

overall progression-free survival

overall survival rate

treatment-related adverse events